BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 34902958)

  • 1. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
    Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
    Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
    Riedinger CJ; Esnakula A; Haight PJ; Suarez AA; Chen W; Gillespie J; Villacres A; Chassen A; Cohn DE; Goodfellow PJ; Cosgrove CM
    Cancer; 2024 Feb; 130(3):385-399. PubMed ID: 37751191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
    Yang SR; Gedvilaite E; Ptashkin R; Chang J; Ziegler J; Mata DA; Villafania LB; Nafa K; Hechtman JF; Benayed R; Zehir A; Benhamida J; Arcila ME; Mandelker D; Rudin CM; Paik PK; Drilon A; Schoenfeld AJ; Ladanyi M
    J Thorac Oncol; 2024 Mar; 19(3):409-424. PubMed ID: 37838086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
    Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
    Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE
    Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High homogeneity of MMR deficiency in ovarian cancer.
    Fraune C; Rosebrock J; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Schmalfeldt B; Müller V; Wölber L; Witzel I; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Clauditz TS; Wilczak W; Sauter G; Steurer S; Burandt E
    Gynecol Oncol; 2020 Mar; 156(3):669-675. PubMed ID: 31924330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of discrepant mismatch repair immunohistochemistry and microsatellite instability polymerase chain reaction test results for gynecologic cancers using next-generation sequencing.
    Smithgall MC; Remotti H; Hsiao SJ; Mansukhani M; Liu-Jarin X; Fernandes H
    Hum Pathol; 2022 Jan; 119():41-50. PubMed ID: 34666078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
    Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
    Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
    Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
    Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.
    Hashmi AA; Mudassir G; Hashmi RN; Irfan M; Asif H; Khan EY; Abu Bakar SM; Faridi N
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2601-2606. PubMed ID: 31554352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications.
    Doghri R; Houcine Y; Boujelbène N; Driss M; Charfi L; Abbes I; Mrad K; Sellami R
    Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):678-682. PubMed ID: 31567138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer.
    Kato MK; Fujii E; Asami Y; Momozawa Y; Hiranuma K; Komatsu M; Hamamoto R; Ebata T; Matsumoto K; Ishikawa M; Kohno T; Kato T; Yoshida H; Shiraishi K
    Cancer Sci; 2024 May; 115(5):1646-1655. PubMed ID: 38433331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An exploration of gastric cancer with heterogeneous mismatch repair status.
    Wang X; Jiang K; Hu Y; Zhao X; Yin L; Diao X; Ma X; Xu Y; Bai Y; Zhang Y; Li Z; Sun Y
    Virchows Arch; 2023 Mar; 482(3):517-523. PubMed ID: 36754896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
    Smyth EC; Wotherspoon A; Peckitt C; Gonzalez D; Hulkki-Wilson S; Eltahir Z; Fassan M; Rugge M; Valeri N; Okines A; Hewish M; Allum W; Stenning S; Nankivell M; Langley R; Cunningham D
    JAMA Oncol; 2017 Sep; 3(9):1197-1203. PubMed ID: 28241187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical Analysis of Mismatch Repair Gene Proteins in Early Gastric Cancer Based on Microsatellite Status.
    Sugimoto R; Endo M; Osakabe M; Toya Y; Yanagawa N; Matsumoto T; Sugai T
    Digestion; 2021; 102(5):691-700. PubMed ID: 33053554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
    Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
    Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mismatch repair protein expression of colorectal cancer: a retrospective analysis of 3 428 cases].
    Liu Y; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Zang FL; Qiu ZQ; Sun BC; Sun Y
    Zhonghua Bing Li Xue Za Zhi; 2021 Apr; 50(4):369-375. PubMed ID: 33831997
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.